Goldman Sachs Group Inc Neurocrine Biosciences Inc Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,017,154 shares of NBIX stock, worth $139 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,017,154
Previous 1,132,589
10.19%
Holding current value
$139 Million
Previous $156 Million
24.9%
% of portfolio
0.02%
Previous 0.03%
Shares
19 transactions
Others Institutions Holding NBIX
# of Institutions
626Shares Held
94MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.94 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.36 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$703 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$352 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$254 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...